Lupin has resolved manufacturing issues raised by the US health regulator regarding its Goa and Pithampur-based manufacturing facilities. The company has received a correspondence from the US Food and Drug Administration (USFDA) that it (Lupin) has now addressed the concerns raised in the warning letter for its facilities in Goa and Pithampur Unit-2. This comes after the satisfactory evaluation of the corrective actions taken by the company in response to the Warning Letter issued by the USFDA on November 6, 2017.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
